수면 보조제 시장 - 세계 예측(2026-2032년)

The Sleep Aids Market is projected to grow by USD 100.59 billion at a CAGR of 5.90% by 2032.

Sleep Aids Executive Summary: A Health-Centered Market Defined by Sleep Quality, Safety, and Personalization

Sleep aids are becoming a central component of modern health management as insomnia, circadian disruption, stress-related sleep disturbance, shift work, aging populations, and digital lifestyle exposure continue to affect sleep quality worldwide. The sleep aids landscape spans prescription and over-the-counter medications, melatonin and botanical supplements, wearable sleep tracking devices, smart mattresses, positive airway pressure devices, sleep masks, light therapy tools, and behavioral support solutions such as cognitive behavioral therapy for insomnia. Demand is shaped by rising awareness that poor sleep is associated with cardiometabolic risk, impaired immune function, mental health burden, reduced workplace productivity, and diminished quality of life. At the same time, regulatory scrutiny, safety concerns around sedative use, and growing consumer preference for non-habit-forming and clinically validated options are reshaping product development. Healthcare providers, retailers, device manufacturers, and digital health innovators are responding with integrated sleep health solutions that combine diagnostics, monitoring, behavior change, and personalized intervention pathways.

Transformative Shifts in Sleep Aids: From Sedation to Integrated Sleep Health Solutions

The sleep aids industry is shifting from symptom-focused products toward holistic sleep health ecosystems. Consumers are increasingly seeking solutions that address root causes such as stress, poor sleep hygiene, environmental disruption, irregular schedules, sleep apnea, and anxiety rather than relying solely on sedatives. This shift has elevated demand for wearable sleep trackers, app-based coaching, non-pharmacological interventions, and clinically supported supplements. Healthcare systems are also placing greater emphasis on diagnosis and ongoing management of sleep disorders, particularly obstructive sleep apnea and chronic insomnia, as evidence links sleep impairment with cardiovascular disease, diabetes, depression, and cognitive decline. Regulatory agencies and professional guidelines continue to influence the use of hypnotics, antihistamines, and supplements by emphasizing safety labeling, appropriate duration of use, and medical supervision where needed. Retail and eCommerce channels are expanding access to sleep support products, while hospitals, sleep clinics, pharmacies, and telehealth platforms are strengthening clinical pathways. The result is a more evidence-oriented landscape in which convenience, safety, interoperability, and measurable outcomes are becoming decisive factors.

Cumulative Impact of Artificial Intelligence on Personalized Sleep Aids and Connected Care

Artificial intelligence is accelerating the evolution of sleep aids by enabling more precise sleep monitoring, personalized recommendations, early risk identification, and automated coaching. AI-enabled wearables and connected devices can analyze signals such as heart rate variability, movement, respiration patterns, blood oxygen saturation, snoring, and sleep-wake cycles to generate actionable insights. In clinical settings, AI-assisted analysis can support sleep study interpretation, improve triage for suspected sleep apnea, and help clinicians identify patterns that may otherwise be missed in large datasets. Digital therapeutics and mobile health applications are using algorithm-driven personalization to adapt sleep hygiene guidance, relaxation techniques, circadian scheduling, and behavioral interventions to individual routines. AI also supports product innovation by helping developers understand adherence barriers, optimize device settings, and monitor real-world outcomes. However, the cumulative impact of AI depends on data quality, algorithm transparency, cybersecurity, privacy compliance, clinical validation, and equity across populations. Industry leaders that pair AI-driven convenience with medically credible evidence are better positioned to build trust among consumers, clinicians, regulators, and payers.

Key Regional Insights: Sleep Aids Adoption Across Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is a high-priority region for sleep aids because rapid urbanization, long working hours, academic pressure, aging demographics, and high smartphone adoption are intensifying interest in sleep tracking, supplements, and accessible digital support. China, Japan, India, South Korea, and Australia show strong momentum across connected devices, melatonin alternatives, herbal sleep products, and clinical sleep disorder management, while local regulatory differences shape product claims and distribution. North America remains a highly developed sleep aids environment supported by widespread consumer awareness, established pharmacy and eCommerce channels, strong adoption of wearables, and active clinical management of insomnia and sleep apnea. In the United States and Canada, safety conversations around prescription hypnotics, antihistamines, and supplement quality are pushing consumers toward evidence-backed and non-habit-forming solutions. Latin America is seeing rising demand as urban stress, changing work patterns, and growing middle-class healthcare spending expand interest in OTC sleep support, natural remedies, and sleep diagnostics, with Brazil and Mexico serving as important demand centers. Europe is characterized by stronger regulatory oversight, mature pharmacy networks, and growing acceptance of digital health and behavioral sleep interventions, with countries emphasizing patient safety, product labeling, and medical guidance. The Middle East is gaining attention as lifestyle-related sleep disruption, high rates of metabolic disease, and expanding private healthcare infrastructure support greater use of sleep clinics, CPAP therapy, and wellness-oriented sleep products. Africa remains diverse and uneven, with demand concentrated in urban centers where pharmacies, private clinics, and digital retail are improving access, while affordability, awareness, and diagnostic infrastructure remain important constraints.

Key Group Insights: Sleep Aids Trends Across ASEAN, GCC, EU, BRICS, G7, and NATO Economies

ASEAN is emerging as a dynamic sleep aids region due to urban population growth, expanding pharmacy retail, increasing digital health adoption, and consumer familiarity with wellness products, with demand shaped by affordability and varying national rules on supplements and OTC medicines. The GCC is gaining relevance as high disposable income, private healthcare expansion, and wellness-focused consumer behavior support premium sleep products, sleep diagnostics, and connected health tools, while hot climates, screen exposure, and lifestyle-related health conditions contribute to sleep disturbance concerns. The European Union plays a significant role through harmonized regulatory principles, pharmacovigilance expectations, data protection requirements, and strong consumer protection frameworks, which influence labeling, clinical substantiation, digital health privacy, and supplement claims. BRICS countries bring scale and diversity to the sleep aids landscape, combining large urban populations, rising healthcare access, strong domestic manufacturing capabilities, and growing eCommerce penetration, although reimbursement systems, regulatory maturity, and income distribution vary considerably. G7 markets are distinguished by mature healthcare systems, higher consumer awareness, advanced sleep diagnostics, established pharmacy channels, and early adoption of wearable and AI-enabled sleep technologies. NATO member countries, many of which overlap with North America and Europe, show demand linked to workforce readiness, veteran health, stress management, and sleep disorder treatment, with institutional interest in fatigue mitigation, mental health, and resilience supporting broader sleep health awareness.

Key Country Insights: Sleep Aids Opportunities Across the United States, China, India, Japan, and Major Economies

The United States is one of the most advanced sleep aids environments, with strong demand across prescription therapies, OTC medications, melatonin products, CPAP devices, wearables, and digital sleep coaching, supported by high awareness of insomnia and sleep apnea. Canada reflects similar patterns, with regulated pharmacy access, growing consumer interest in natural sleep support, and expanding use of telehealth and sleep diagnostics. Mexico is experiencing greater demand for OTC sleep support and pharmacy-led access as urban stress and changing work schedules influence sleep habits. Brazil is a major Latin American sleep health market, where urbanization, wellness retail, and interest in natural and pharmaceutical sleep aids are increasing alongside sleep disorder awareness. The United Kingdom emphasizes patient safety, pharmacy consultation, and behavioral approaches, with strong adoption of consumer sleep technology and digital health services. Germany combines a robust healthcare system, high standards for medical products, and consumer demand for evidence-based sleep solutions, including sleep apnea devices and clinically oriented interventions. France shows strong pharmacy influence and regulatory attention to appropriate medication use, encouraging interest in safer and non-pharmacological options. Russia has demand shaped by urban stress, OTC pharmacy access, and growing attention to sleep quality, though regional access and regulatory conditions vary. Italy and Spain both show rising wellness-oriented sleep aid use, supported by pharmacy networks, aging populations, and interest in supplements and behavioral support. China is rapidly expanding across connected sleep devices, smart home sleep environments, traditional wellness approaches, and digital health platforms, while regulatory oversight increasingly affects product quality and health claims. India is seeing increasing demand driven by urbanization, digital lifestyles, shift work, stress, and rising awareness of sleep disorders, with affordability and access shaping adoption. Japan has strong relevance due to aging demographics, long working hours, high technology adoption, and consumer interest in sleep improvement products. Australia benefits from mature healthcare access, high awareness of sleep apnea, active use of CPAP therapy, and growing uptake of wearables and behavioral sleep tools. South Korea combines high digital connectivity, work-related sleep challenges, beauty and wellness retail sophistication, and strong consumer interest in sleep tracking, supplements, and smart home sleep solutions.

Actionable Recommendations for Sleep Aids Industry Leaders

Industry leaders should prioritize clinically credible, user-friendly sleep aids that address safety, adherence, and measurable improvement in sleep quality. Product portfolios should balance pharmacological, non-pharmacological, supplement, device, and digital solutions while clearly differentiating between occasional sleeplessness, chronic insomnia, circadian rhythm disruption, and sleep-disordered breathing. Organizations should invest in clinical validation, transparent labeling, adverse event monitoring, and education for consumers and healthcare professionals. AI-enabled tools should be designed with privacy-by-default architecture, explainable algorithms, and inclusive datasets that represent different ages, genders, ethnicities, and health profiles. Partnerships with sleep clinics, pharmacies, primary care providers, mental health professionals, employers, and digital health platforms can strengthen adoption and continuity of care. Companies should also localize formulations, claims, pricing, and distribution strategies to align with regional regulations and cultural preferences. The strongest competitive positioning will come from solutions that combine convenience, evidence, personalization, affordability, and responsible use guidance.

Research Methodology: Evidence-Based Assessment of Sleep Aids Trends and Adoption Drivers

This executive summary is developed through structured secondary research and evidence synthesis using publicly available and authoritative sources, including health agency publications, clinical guidelines, peer-reviewed medical literature, regulatory communications, product safety information, digital health policy references, and sleep medicine research. The methodology focuses on validated indicators such as sleep disorder prevalence patterns, healthcare access, regulatory direction, technology adoption, pharmacy and eCommerce development, demographic trends, and clinical practice evolution. Regional, group, and country insights are interpreted through a comparative framework that considers consumer behavior, healthcare infrastructure, regulatory maturity, digital readiness, and product accessibility. The analysis intentionally excludes market sizing, market estimation, market share, and forecasting, focusing instead on qualitative and evidence-backed strategic intelligence. Each insight is assessed for relevance to sleep aids, including prescription and OTC products, supplements, connected devices, sleep diagnostics, behavioral interventions, and AI-enabled tools.

Conclusion: Sleep Aids Are Evolving Toward Safer, Smarter, and More Personalized Sleep Health

The sleep aids landscape is entering a more sophisticated phase defined by personalization, safety, connected monitoring, and clinical credibility. Consumers are increasingly aware that sleep quality is foundational to physical health, mental resilience, cognitive performance, and daily productivity. This awareness is expanding demand beyond traditional sedatives toward integrated solutions that combine diagnostics, coaching, environmental optimization, supplements, devices, and medically guided treatment. Artificial intelligence and wearable technologies are improving the ability to understand sleep patterns, but long-term trust will depend on transparent validation, data protection, and responsible claims. Regional and country dynamics vary substantially, requiring localized strategies that reflect healthcare systems, cultural preferences, regulatory expectations, and purchasing behavior. Industry participants that place evidence, safety, affordability, and user engagement at the center of strategy will be best positioned to support better sleep outcomes in an increasingly health-conscious global environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Sleep Aids Market, by Product Type

• 7.1. Introduction
• 7.2. Over The Counter
  • 7.2.1. Antihistamines
  • 7.2.2. Herbal Supplements
  • 7.2.3. Melatonin
• 7.3. Prescription
  • 7.3.1. Benzodiazepines
  • 7.3.2. Non-Benzodiazepine Hypnotics
  • 7.3.3. Orexin Receptor Antagonists
• 7.4. Sleep Therapy Devices
  • 7.4.1. Light Therapy Devices
  • 7.4.2. Oral Appliances
  • 7.4.3. Positive Airway Pressure Devices
  • 7.4.4. Sound Machines
• 7.5. Wearable Devices
  • 7.5.1. Fitness Bands
  • 7.5.2. Sleep Trackers
  • 7.5.3. Smartwatches

8. Sleep Aids Market, by Sleep Disorder Type

• 8.1. Introduction
• 8.2. Insomnia
  • 8.2.1. Sleep Onset Insomnia
  • 8.2.2. Sleep Maintenance Insomnia
  • 8.2.3. Mixed Insomnia
• 8.3. Sleep Apnea
  • 8.3.1. Obstructive Sleep Apnea
  • 8.3.2. Central Sleep Apnea
• 8.4. Circadian Rhythm Disorders
  • 8.4.1. Delayed Sleep Phase Disorder
  • 8.4.2. Advanced Sleep Phase Disorder
  • 8.4.3. Shift Work Sleep Disorder
• 8.5. Hypersomnia & Narcolepsy
  • 8.5.1. Narcolepsy
  • 8.5.2. Idiopathic Hypersomnia
• 8.6. Parasomnias
  • 8.6.1. Nightmares & Night Terrors
  • 8.6.2. Sleepwalking & Sleep Talking
  • 8.6.3. REM Sleep Behavior Disorder
• 8.7. Restless Legs & Movement Disorders
  • 8.7.1. Restless Legs Syndrome
  • 8.7.2. Periodic Limb Movement Disorder
• 8.8. General Sleep Quality & Recovery

9. Sleep Aids Market, by Dosage Form

• 9.1. Introduction
• 9.2. Solid Oral
  • 9.2.1. Tablets
  • 9.2.2. Capsules
  • 9.2.3. Gummies & Chews
  • 9.2.4. Lozenges
• 9.3. Liquid Oral
  • 9.3.1. Solutions
  • 9.3.2. Suspensions
  • 9.3.3. Syrups
  • 9.3.4. Drops
• 9.4. Sublingual & Orodispersible
  • 9.4.1. Sublingual Sprays
  • 9.4.2. Orodispersible Tablets & Strips
• 9.5. Topical & Transdermal
  • 9.5.1. Creams & Gels
  • 9.5.2. Patches
  • 9.5.3. Oils & Balms
• 9.6. Inhalation & Aromatic
  • 9.6.1. Diffuser Oils
  • 9.6.2. Pillow Sprays

10. Sleep Aids Market, by End User

• 10.1. Introduction
• 10.2. Adults
• 10.3. Geriatric
• 10.4. Pediatric

11. Sleep Aids Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online
• 11.4. Retail Pharmacies
• 11.5. Specialty Stores

12. Sleep Aids Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Sleep Aids Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Sleep Aids Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Bayer AG
• 16.2. Cadwell Industries, Inc.
• 16.3. CVS Health Corporation
• 16.4. Dr. Reddy's Laboratories Ltd.
• 16.5. Drive DeVilbiss Healthcare
• 16.6. Eisai Co., Ltd.
• 16.7. Fisher & Paykel Healthcare Corporation Limited
• 16.8. GlaxoSmithKline plc
• 16.9. Haleon PLC
• 16.10. Herbalife Nutrition Ltd.
• 16.11. Hikma Pharmaceuticals PLC
• 16.12. Jamieson Wellness Inc.
• 16.13. Johnson & Johnson Services In
• 16.14. Koninklijke Philips N.V.
• 16.15. Medtronic plc
• 16.16. Merck & Co., Inc.
• 16.17. Natrol LLC
• 16.18. Neurim Pharmaceuticals Ltd.
• 16.19. Novartis AG
• 16.20. Perrigo Company PLC
• 16.21. Pfizer Inc.
• 16.22. Reckitt Benckiser Group plc
• 16.23. Sanofi SA
• 16.24. Serta Simmons Bedding, LLC
• 16.25. Sleep Number Corporation
• 16.26. SomnoMed Limited
• 16.27. Takeda Pharmaceutical Company Limited
• 16.28. Tempur Sealy International, Inc.
• 16.29. The Bountiful Company
• 16.30. Unilever PLC
• 16.31. Vanda Pharmaceuticals Inc.
• 16.32. Viatris Inc.